efdege 1 gbq/ml raztopina za injiciranje
iason gmbh - fluorodeoksiglukoza - raztopina za injiciranje - fluorodeoksiglukoza 1 gbq / 1 ml - [18f]fludeoksiglukoza
fdg (f18)-bsm injection solution 11,1 gbq raztopina za injiciranje
biomedis m.b. d.o.o. - raztopina za injiciranje - [18f]fludeoksiglukoza
fdg (f18)-bsm injection solution 5,92 gbq raztopina za injiciranje
biomedis m.b. d.o.o. - raztopina za injiciranje - [18f]fludeoksiglukoza
fdg (f18)-bsm injection solution 9,62 gbq raztopina za injiciranje
biomedis m.b. d.o.o. - raztopina za injiciranje - [18f]fludeoksiglukoza
fdg (f18)-bsm injection solution 8,14 gbq raztopina za injiciranje
biomedis m.b. d.o.o. - raztopina za injiciranje - [18f]fludeoksiglukoza
fdg (f18)-bsm injection solution 10,36 gbq raztopina za injiciranje
biomedis m.b. d.o.o. - raztopina za injiciranje - [18f]fludeoksiglukoza
fdg (f18)-bsm injection solution 4,44 gbq raztopina za injiciranje
biomedis m.b. d.o.o. - raztopina za injiciranje - [18f]fludeoksiglukoza
fdg (f18)-bsm injection solution 8,88 gbq raztopina za injiciranje
biomedis m.b. d.o.o. - raztopina za injiciranje - [18f]fludeoksiglukoza
fdg (f18)-bsm injection solution 6,66 gbq raztopina za injiciranje
biomedis m.b. d.o.o. - raztopina za injiciranje - [18f]fludeoksiglukoza
orserdu
stemline therapeutics b.v. - elacestrant - neoplazme dojke - endokrini terapija - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.